{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:31:31Z","timestamp":1772767891089,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semradonc.2025.07.004","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:28:07Z","timestamp":1757514487000},"page":"538-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality and Quantity: Dual Benefits of Ablative Radiation in Oligometastatic Pancreatic Cancer"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-3758","authenticated-orcid":false,"given":"Todd A.","family":"Aguilera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M.","family":"Elamir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan B.","family":"Ludmir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semradonc.2025.07.004_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.semradonc.2025.07.004_bib0002","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.pan.2021.01.014","article-title":"The impact of different metastatic patterns on survival in patients with pancreatic cancer","volume":"21","author":"He","year":"2021","journal-title":"Pancreatol: Offic J Int Assoc Pancreatol (IAP) [et al.]"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.004_bib0003","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1186\/s12885-019-6448-9","article-title":"Proposal for a definition of \u201coligometastatic disease in pancreatic cancer\u201d","volume":"19","author":"Damanakis","year":"2019","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.semradonc.2025.07.004_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102067","article-title":"Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus","volume":"8","author":"Leonhardt","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.004_bib0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"10185","key":"10.1016\/j.semradonc.2025.07.004_bib0006","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semradonc.2025.07.004_bib0007","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.07.004_bib0008","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.07.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.004_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(23)00316-3","article-title":"Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial","volume":"9","author":"Liu","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.07.004_bib0011","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"issue":"36","key":"10.1016\/j.semradonc.2025.07.004_bib0012","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.004_bib0013","article-title":"Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): a multicenter, randomized phase II trial","author":"Ludmir","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.004_bib0015","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.07.004_bib0016","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.07.004_bib0017","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ijrobp.2022.07.019","article-title":"Ablative radiation therapy in oligometastatic pancreatic cancer to delay polyprogression, limit chemotherapy, and improve outcomes","volume":"114","author":"Elamir","year":"2022","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"issue":"13","key":"10.1016\/j.semradonc.2025.07.004_bib0018","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/1078-0432.CCR-21-0612","article-title":"Alternatives to perpetual chemotherapy for metastatic pancreatic cancer","volume":"27","author":"Reiss","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.semradonc.2025.07.004_bib0019","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO.23.01402","article-title":"Elucidating the benefit of radiation therapy in GI cancers: rethinking trial end points and patient selection","volume":"42","author":"Sanford","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.07.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.618","article-title":"Unraveling the oligometastatic phenotype and its association with pancreatic cancer survival","author":"Karalis JDE","year":"2022","journal-title":"J Clin Oncol;"},{"issue":"19","key":"10.1016\/j.semradonc.2025.07.004_bib0021","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"New Engl J Med"},{"issue":"18","key":"10.1016\/j.semradonc.2025.07.004_bib0022","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"New Engl J Med"},{"key":"10.1016\/j.semradonc.2025.07.004_bib0023","article-title":"Post-progression survival in patients with oligometastatic or polymetastatic pancreatic adenocarcinoma","author":"Elamir","year":"2023","journal-title":"IJROBP;"},{"issue":"1106","key":"10.1016\/j.semradonc.2025.07.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190627","article-title":"Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question","volume":"93","author":"Scorsetti","year":"2020","journal-title":"Br J Radiol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.07.004_bib0025","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/MPA.0000000000001822","article-title":"Liver metastasis-directed ablative radiotherapy in pancreatic cancer offers prolonged time off systemic therapy in selected patients: data from a multi-institutional retrospective study","volume":"50","author":"Lee","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.semradonc.2025.07.004_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/10732748231219069","article-title":"Ablative 5-fraction stereotactic MRI-guided adaptive radiotherapy for oligometastatic pancreatic adenocarcinoma","volume":"30","author":"Webking","year":"2023","journal-title":"Cancer Control"},{"key":"10.1016\/j.semradonc.2025.07.004_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659987","article-title":"Clinical effects of stereotactic body radiation therapy targeting the primary tumor of liver-only oligometastatic pancreatic cancer","volume":"11","author":"Ji","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2025.07.004_bib0028","doi-asserted-by":"crossref","first-page":"7912","DOI":"10.3390\/curroncol29100625","article-title":"The effects of radiotherapy on pancreatic ductal adenocarcinoma in patients with liver metastases","volume":"29","author":"Wu","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.semradonc.2025.07.004_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1225979","article-title":"Survival benefit of local consolidative therapy for patients with single-organ metastatic pancreatic cancer: a propensity score-matched cross-sectional study based on 17 registries","volume":"14","author":"Hu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.004_bib0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1089\/pancan.2018.0011","article-title":"Survival of patients with oligometastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: a pilot study","volume":"4","author":"Kandel","year":"2018","journal-title":"J Pancreat Cancer"},{"issue":"1","key":"10.1016\/j.semradonc.2025.07.004_bib0031","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12885-019-5630-4","article-title":"Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study","volume":"19","author":"Gbolahan","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semradonc.2025.07.004_bib0032","article-title":"MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma","author":"Maddipati","year":"2021","journal-title":"Cancer Discov"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:38:08Z","timestamp":1772764688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1053429625000591"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.07.004","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality and Quantity: Dual Benefits of Ablative Radiation in Oligometastatic Pancreatic Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}